The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations

Alan J. Garber, Lawrence Blonde, Zachary T. Bloomgarden, Yehuda Handelsman, Samuel Dagogo-Jack

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods: Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, including peer-reviewed abstracts and poster presentations. Results: BQR is an oral hypoglycemic agent with a novel mechanism of action that appears to involve enhancement of morning central nervous system (CNS) dopaminergic activity, resulting in improved insulin sensitivity and reduced hepatic glucose output. Adjunctive treatment with BQR in the dosing range of 1.6 to 4.8 mg/d may result in a mean (95% confidence interval [CI]) reduction in glycated hemoglobin (A1c) levels of 0.69% (0.97%, 0.41%). Treatment with BQR appears to be associated with minimal intrinsic risk of hypoglycemia, and does not appear to be associated with clinically significant adverse effects on weight, triglycerides, free fatty acids, or blood pressure. Conclusion: The favorable cardiovascular risk profile of BQR suggests that it may be useful in the treatment of patients with T2DM with a history of cardiovascular disease (CVD) or who have significant risk factors for CVD. However, knowledge of the efficacy and safety of BQR is limited by the relatively small clinical trials database. As a result, there is currently insufficient information on the safety and efficacy of adjunctive BQR in T2DM patients being treated with several common diabetes regimens (e.g., thiazolidinediones, insulin).

Original languageEnglish (US)
Pages (from-to)100-106
Number of pages7
JournalEndocrine Practice
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Bromocriptine
Type 2 Diabetes Mellitus
Safety
Cardiovascular Diseases
Thiazolidinediones
Posters
Glycosylated Hemoglobin A
Therapeutics
Hypoglycemia
Nonesterified Fatty Acids
Hypoglycemic Agents
Insulin Resistance
Triglycerides
Central Nervous System
Clinical Trials
Databases
Confidence Intervals
Insulin
Blood Pressure
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. / Garber, Alan J.; Blonde, Lawrence; Bloomgarden, Zachary T.; Handelsman, Yehuda; Dagogo-Jack, Samuel.

In: Endocrine Practice, Vol. 19, No. 1, 01.01.2013, p. 100-106.

Research output: Contribution to journalArticle

Garber, Alan J. ; Blonde, Lawrence ; Bloomgarden, Zachary T. ; Handelsman, Yehuda ; Dagogo-Jack, Samuel. / The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. In: Endocrine Practice. 2013 ; Vol. 19, No. 1. pp. 100-106.
@article{f726d2a71741457989cfdee340f1f592,
title = "The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations",
abstract = "Objective: To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods: Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, including peer-reviewed abstracts and poster presentations. Results: BQR is an oral hypoglycemic agent with a novel mechanism of action that appears to involve enhancement of morning central nervous system (CNS) dopaminergic activity, resulting in improved insulin sensitivity and reduced hepatic glucose output. Adjunctive treatment with BQR in the dosing range of 1.6 to 4.8 mg/d may result in a mean (95{\%} confidence interval [CI]) reduction in glycated hemoglobin (A1c) levels of 0.69{\%} (0.97{\%}, 0.41{\%}). Treatment with BQR appears to be associated with minimal intrinsic risk of hypoglycemia, and does not appear to be associated with clinically significant adverse effects on weight, triglycerides, free fatty acids, or blood pressure. Conclusion: The favorable cardiovascular risk profile of BQR suggests that it may be useful in the treatment of patients with T2DM with a history of cardiovascular disease (CVD) or who have significant risk factors for CVD. However, knowledge of the efficacy and safety of BQR is limited by the relatively small clinical trials database. As a result, there is currently insufficient information on the safety and efficacy of adjunctive BQR in T2DM patients being treated with several common diabetes regimens (e.g., thiazolidinediones, insulin).",
author = "Garber, {Alan J.} and Lawrence Blonde and Bloomgarden, {Zachary T.} and Yehuda Handelsman and Samuel Dagogo-Jack",
year = "2013",
month = "1",
day = "1",
doi = "10.4158/EP12325.OR",
language = "English (US)",
volume = "19",
pages = "100--106",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "1",

}

TY - JOUR

T1 - The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations

AU - Garber, Alan J.

AU - Blonde, Lawrence

AU - Bloomgarden, Zachary T.

AU - Handelsman, Yehuda

AU - Dagogo-Jack, Samuel

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods: Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, including peer-reviewed abstracts and poster presentations. Results: BQR is an oral hypoglycemic agent with a novel mechanism of action that appears to involve enhancement of morning central nervous system (CNS) dopaminergic activity, resulting in improved insulin sensitivity and reduced hepatic glucose output. Adjunctive treatment with BQR in the dosing range of 1.6 to 4.8 mg/d may result in a mean (95% confidence interval [CI]) reduction in glycated hemoglobin (A1c) levels of 0.69% (0.97%, 0.41%). Treatment with BQR appears to be associated with minimal intrinsic risk of hypoglycemia, and does not appear to be associated with clinically significant adverse effects on weight, triglycerides, free fatty acids, or blood pressure. Conclusion: The favorable cardiovascular risk profile of BQR suggests that it may be useful in the treatment of patients with T2DM with a history of cardiovascular disease (CVD) or who have significant risk factors for CVD. However, knowledge of the efficacy and safety of BQR is limited by the relatively small clinical trials database. As a result, there is currently insufficient information on the safety and efficacy of adjunctive BQR in T2DM patients being treated with several common diabetes regimens (e.g., thiazolidinediones, insulin).

AB - Objective: To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods: Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, including peer-reviewed abstracts and poster presentations. Results: BQR is an oral hypoglycemic agent with a novel mechanism of action that appears to involve enhancement of morning central nervous system (CNS) dopaminergic activity, resulting in improved insulin sensitivity and reduced hepatic glucose output. Adjunctive treatment with BQR in the dosing range of 1.6 to 4.8 mg/d may result in a mean (95% confidence interval [CI]) reduction in glycated hemoglobin (A1c) levels of 0.69% (0.97%, 0.41%). Treatment with BQR appears to be associated with minimal intrinsic risk of hypoglycemia, and does not appear to be associated with clinically significant adverse effects on weight, triglycerides, free fatty acids, or blood pressure. Conclusion: The favorable cardiovascular risk profile of BQR suggests that it may be useful in the treatment of patients with T2DM with a history of cardiovascular disease (CVD) or who have significant risk factors for CVD. However, knowledge of the efficacy and safety of BQR is limited by the relatively small clinical trials database. As a result, there is currently insufficient information on the safety and efficacy of adjunctive BQR in T2DM patients being treated with several common diabetes regimens (e.g., thiazolidinediones, insulin).

UR - http://www.scopus.com/inward/record.url?scp=84881535678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881535678&partnerID=8YFLogxK

U2 - 10.4158/EP12325.OR

DO - 10.4158/EP12325.OR

M3 - Article

C2 - 23337160

AN - SCOPUS:84881535678

VL - 19

SP - 100

EP - 106

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 1

ER -